Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer
Recruitment status was Active, not recruiting
RATIONALE: DNA analysis of tumor tissue may help doctors predict how patients who receive paclitaxel will respond to treatment.
PURPOSE: This laboratory study is evaluating gene expression in predicting response to paclitaxel in patients with breast cancer.
Genetic: cytogenetic analysis
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: mutation analysis
Genetic: reverse transcriptase-polymerase chain reaction
Other: immunohistochemistry staining method
|Official Title:||Determination Of FEZ1/LZTS1 Expression As A Predictor Of Response To Taxol|
- Evaluation of the association between tumor expression of FEZ1/LZTS1 gene and response to paclitaxel [ Designated as safety issue: No ]
- Utility of FEZ1/LZTS1 gene expression in predicting the full 4-level response pattern (complete response, partial response, stable disease, progressive disease) [ Designated as safety issue: No ]
|Study Start Date:||March 2003|
- Determine whether loss of function of the FEZ1/LZTS1 gene is a predictor of response in patients with breast cancer treated with paclitaxel.
OUTLINE: This is a single-blind study.
Tumor tissue is analyzed for FEZ1/LZTS1 gene expression by immunohistochemistry using an antibody for the gene. Tumor expression of the gene is characterized by immunohistochemistry and scored by intensity of staining, percent of cell staining, and staining index. Tumor tissue is also analyzed for FEZ1/LZTS1 gene disruption by reverse transcriptase-polymerase chain reaction and direct sequencing.
PROJECTED ACCRUAL: Approximately 120 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898690
|Principal Investigator:||Carlo M. Croce, MD||Kimmel Cancer Center (KCC)|